Disease · MONDO_0018876
Comparisons in its trials54
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 54
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Placebo + Bendamustine and Rituximab (BR) (Treatment A) vs Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B): deaths from any cause | 129 of 262 | 120 of 261 | 523 | NCT01776840 | Trial comparisons |
| Placebo + Bendamustine and Rituximab (BR) (Treatment A) vs Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B): Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 257 of 260 | 259 of 259 | 519 | NCT01776840 | Trial comparisons |
| Placebo + Bendamustine and Rituximab (BR) (Treatment A) vs Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B): serious adverse events | 157 of 260 | 201 of 259 | 519 | NCT01776840 | Trial comparisons |
| R-CHOP vs VcR-CAP: Number of Participants Experiencing an Adverse Event (AE) | 239 of 242 | 240 of 240 | 482 | NCT00722137 | Trial comparisons |
| R-CHOP vs VcR-CAP: serious adverse events | 72 of 242 | 91 of 240 | 482 | NCT00722137 | Trial comparisons |
| R-CHOP vs VcR-CAP: Overall Response Rate (ORR) | 204 of 228 | 211 of 229 | 457 | NCT00722137 | Trial comparisons |
| Bendamustine and Rituximab (BR) vs R-CHOP/R-CVP: Participants With Disease Progression, Relapse or Death At the End of the Treatment Period or the Long-Term Follow-up Period | 36 of 224 | 30 of 223 | 447 | NCT00877006 | Trial comparisons |
| Bendamustine and Rituximab (BR) vs R-CHOP/CVP: serious adverse events | 60 of 221 | 49 of 215 | 436 | NCT00877006 | Trial comparisons |
| Mitoxantrone, Chlorambucil, Prednisolone (MCP) vs Rituximab + MCP: serious adverse events | 20 of 177 | 18 of 183 | 360 | NCT00269113 | Trial comparisons |
Ibrutinib vs Temsirolimus: Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib | 61 of 139 | 53 of 141 | 280 | NCT01646021 | Trial comparisons |
| Ibrutinib vs Temsirolimus: Number of Participants Affected With Treatment-emergent Adverse Events | 139 of 139 | 138 of 139 | 278 | NCT01646021 | Trial comparisons |
| Ibrutinib vs Temsirolimus: deaths from any cause | 130 of 139 | 137 of 139 | 278 | NCT01646021 | Trial comparisons |
| Ibrutinib vs Temsirolimus: serious adverse events | 79 of 139 | 83 of 139 | 278 | NCT01646021 | Trial comparisons |
| Lenalidomide vs Investigator's Choice: deaths from any cause | 119 of 167 | 59 of 83 | 250 | NCT00875667 | Trial comparisons |
| Lenalidomide vs Investigator's Choice: serious adverse events | 75 of 167 | 22 of 83 | 250 | NCT00875667 | Trial comparisons |
| Arm A Maintenance Therapy vs Arm B Consolidation Therapy: Number of Participants With Complete Response Intensive Chemo-immunotherapy Plus Maintenance or Consolidation Bortezomib | 31 of 52 | 35 of 80 | 132 | NCT00310037 | Trial comparisons |
| Step 1 - VcR-CVAD Induction vs Step 2 - Maintenance Rituximab: serious adverse events | 72 of 77 | 16 of 45 | 122 | NCT00433537 | Trial comparisons |
| Rituximab-CHOP-Bortezomib (R-CHOP-V) Induction vs Bortezomib Maintenance (VM): serious adverse events | 1 of 65 | 0 of 47 | 112 | NCT00376961 | Trial comparisons |
| Arm A Maintenance Therapy vs Arm B Consolidation Therapy: Number of Participants With Grade 3, 4 or 5 Adverse Event at Least Possibly Related to Treatment. | 52 of 52 | 50 of 50 | 102 | NCT00310037 | Trial comparisons |
| Arm A Maintenance Therapy vs Arm B Consolidation Therapy: serious adverse events | 13 of 52 | 10 of 50 | 102 | NCT00310037 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018876/comparisons